Vincenzo Gioia

Sep 6, 2024 | lifescienceleader.com | Vincenzo Gioia

By Vincenzo Gioia and Remco Jan Geukes Foppen The rapid adoption of AI in the pharmaceutical market has led to a revolution in the research process and pharmaceutical development techniques. The AI revolution is not free of risks, however. This is why the EU AI Act and President Biden's 2023 took effect highlighting the global importance of secure and trustworthy AI development and use.

Jul 23, 2024 | drugdiscoveryonline.com | Vincenzo Gioia |David Lyon |Molly Adam |John Baumann

Webinar: Innovative AI-Driven Solutions to Address the Growing Complexity of APIsDiscover CASP technologies - the award-winning AI and vast data that propel Lonza’s leading predictive retrosynthesis technology, used to mitigate the impact of rising small mol API complexity and its resulting longer syntheses.

Jul 11, 2024 | lifescienceleader.com | Vincenzo Gioia

By Vincenzo Gioia and Remco Jan Geukes Foppen In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning.

Jul 11, 2024 | bioprocessonline.com | Vincenzo Gioia

By Vincenzo Gioia and Remco Jan Geukes Foppen In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning.

Jun 7, 2024 | lifescienceleader.com | Vincenzo Gioia

By Vincenzo Gioia and Remco Jan Geukes Foppen AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical issues and the risk that AI may perform incorrect calculations. Among this type of error, the most insidious type is represented by the phenomenon of AI hallucinations, which are becoming a persistent concern.